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We have previously shown that peroxisome proliferator-activated receptor-γ (PPARγ) agonists inhibited the inflammatory response of RSV-
infected human lung epithelial cells. In this study, we supply evidence that specific PPARγ agonists (15d-PGJ2, ciglitazone, troglitazone, Fmoc-
Leu) efficiently blocked the RSV-induced cytotoxicity and development of syncytia in tissue culture (A549, HEp-2). All PPARγ agonists under
study markedly inhibited the cell surface expression of the viral G and F protein on RSV-infected A549 cells. This was paralleled by a reduced
cellular amount of N protein-encoding mRNA determined by real-time RT-PCR. Concomitantly, a reduced release of infectious progeny virus into
the cell supernatants of human lung epithelial cells (A549, normal human bronchial epithelial cells (NHBE)) was observed. Similar results were
obtained regardless whether PPARγ agonists were added prior to RSV infection or thereafter, suggesting that the agonists inhibited viral gene
expression and not the primary adhesion or fusion process.
© 2006 Elsevier Inc. All rights reserved.Keywords: RSV; PPARγ; Ciglitazone; Troglitazone; 15d-PGJ2; PPARα; Bezafibrate; NHBE; A549; HEp-2Introduction
Respiratory syncytial virus (RSV) is the leading cause of
serious respiratory tract infections in infants and young children
throughout the world (Hall andMcCarthy, 2000). It accounts for
approximately 125,000 pediatric hospitalizations and up to 450
deaths of children each year in the United States (Shay et al.,
2001). It has been recognized as a major cause of morbidity and
mortality in immunocompromised patients, the elderly, and
children with underlying lung–heart diseases (McDonald et al.,
1982; Falsey et al., 1995; Glezen et al., 2000). Despite nearly
five decades of intensive RSV research, there exist neither an
effective active vaccination nor a promising anti-inflammatory
therapy (Kimpen, 2001). The prophylactic administration of a
humanized monoclonal anti-RSV antibody is highly effective
but costly and currently only recommended for high-risk
children up to 2 years of age, i.e., premature infants and children
with bronchopulmonary dysplasia or congenital heart disease
(IMPACT-RSV Study Group, 1998). Moreover, the value of⁎ Corresponding author. Fax: +49 391 6713384.
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doi:10.1016/j.virol.2006.03.008ribavirin, the only licensed anti-RSV preparation, has been
increasingly questioned in the past (American Academy of
Pediatrics Committee on Infectious Diseases, 1996). During the
last several years, a variety of RSVantiviral substances has been
described (Torrence, 2000; Brooks et al., 2004). Different
promising inhibitors of the F protein were generated (Cianci et
al., 2004; Douglas et al., 2005), but due to the lack of a
proofreading mechanism of the RNA polymerase, the selection
of drug-resistant RSV variants is a major problem (Douglas et
al., 2005; Zhao and Sullender, 2005). Due to their property to
inhibit the virus–host infection process, these drugs would be
primarily useful as a prophylactic agent. Quite recently, a
successful inhibition of respiratory syncytial virus replication
obtained by nasally administered siRNAwas reported (Bitko et
al., 2005). Considerable therapeutic value was observed when
used as a prophylactic as well as a treatment drug after infection.
However, currently neither of these substances is approved for
the treatment of RSV infection.
Therefore, it remains an important task to develop novel
therapeutical targets. A better understanding of the cellular
signaling transduction pathways which are intimately involved
in the RSV replication process is of major importance. It is
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the target for RSV infection, results in a prominent activation of
the transcription factor NF-κB leading to the expression of a
wide spectrum of immune response genes (Tian et al., 2002).
Quite recently, Reimers et al. reported that the viral M2-1
protein mediates the activation of NF-κB by direct protein–
protein interaction (Reimers et al., 2005). However, the
activation of NF-κB is dependent on RSV replication and not
vice versa (Fiedler et al., 1996). In contrast, when NF-κB is
activated either by TNF-α or by IL-1β prior to RSV infection,
this transcription factor is capable of signaling an innate
antiviral response that is independent of IFN and the JAK/STAT
pathway (Bose et al., 2003). In addition, the blocking of STAT-
1α or Map kinase ERK-1/2 activity attenuates RSV gene
transcription and infection (Kong et al., 2003, 2004). Interest-
ingly, the nonstructural RSV proteins NS1 and NS2 are
discussed as viral evasion factors. They inhibit the expression
of Stat2 and block thereby the antiviral α/β interferon response
of the target cell (Lo et al., 2005). Nevertheless, despite of these
first insights, a detailed knowledge of the activated cellular
signal transduction pathways involved in the RSV replication
process in infected human lung epithelial cell is still lacking.
Peroxisome proliferator-activated receptors (PPARs) are
ligand-activated transcription factors which form a subfamily
of the nuclear receptor gene family consisting of three isotypes:
PPARα, PPARβ, and PPARγ (Lee et al., 2003). They regulate
the transcription of distinct genes through heterodimerization
with the retinoid X receptors (RXR). They were first identified
as regulators of the lipid and glucose metabolism (Evans et al.,
2004), but during the last decade, data accumulated showing
that PPARs may also be involved in the complex regulation of
immune and inflammatory processes (Daynes and Jones, 2002).
The activation of PPARα and PPARγ correlated with the
inhibition of inflammatory cell responses in a variety of cell
types and the lung (Clark, 2002; Standiford et al., 2005). In
addition, it has been shown that some viruses may exploit these
ligand-activated transcription factors of the nuclear hormone
receptor family for their own growth advantage. For example,
the hepatitis B virus uses the nuclear hormone receptor RXRα
and the peroxisome proliferator-activated receptor α (PPARα)
for its own replication cycle in liver cells (Tang and McLachan,
2001). Also, the HIV controls, at least partly, its replication by
the interaction of the virus encoded Nef protein with the PPARγ
of the host cell (Otake et al., 2004). Therefore, the objective of
the present study was to assess whether PPAR agonists might
influence the replication of RSV in human lung epithelial cells.
We analyzed the following specific PPARγ agonists in our
study: the natural ligand 15-deoxy-Δ12,14-prostaglandin J2
(15d-PGJ2), the synthetic agonist Fmoc-Leu, as well as the
recently FDA approved antidiabetic thiazolidinedione deriva-
tives ciglitazone and troglitazone, respectively. Besides the
different specific PPARγ agonists, we also included the
hypolipidemic drug bezafibrate, as a representative PPARα
ligand.
In this study, we supply evidence that the synthetic PPARγ
agonists Fmoc-Leu, ciglitazone, troglitazone, and the natural
PPARγ ligand 15d-PGJ2 profoundly protected epithelialmonolayers (HEp-2, A549) from cytopathic effects up to 48 h
post-infection. After 3 days post-infection, only the synthetic
PPARγ agonists were still able to protect the RSV-infected cell
monolayer from detrimental major cytopathic cell damage. The
RSV-infected human lung A549 epithelial cells cultured in the
presence of the PPARγ ligands under study expressed a reduced
amount of the cell surface bound viral G and F protein.
Concomitantly, a downregulated viral N protein mRNA level
was observed. This coincided with a markedly reduced release
of infectious progeny virus from RSV-infected lung epithelial
cells (A549, NHBE). In addition, the potential use of these
PPARγ agonists in the light of RSV-infection is discussed.
Results
Expression profile of PPAR isoforms in A549 cells
Since A549 cells are a well-accepted in vitro RSV infection
model, we used these cells to analyze which of the PPAR
isotypes are expressed in these human airway epithelial cells at
the protein level. The cells were permeabilized and stained
intracellularly with isoform-specific polyclonal Abs. The
immunofluorescence signals were determined by FACS anal-
ysis. As shown in Fig. 1, A549 cells expressed high amounts of
all three isoforms of PPAR in a constitutive manner. When the
primary unlabeled Abs were omitted, the cells showed no
remaining immunofluorescence signal verifying that the second
labeled Abs did not stain the cells in an unspecific manner (data
not shown). Additionally, prior to cell staining, an excess of
blocking peptides specific for the used PPARα- and PPARγ-
specific Abs was added to the primary Abs. These pretreated
PPAR-specific Abs did not stain A549 cells anymore proving
binding specificity of the used Abs (Figs. 1A and B).
Increased cell viability of RSV-infected epithelial cell
monolayer exposed to PPARγ agonists
To assess whether activation of PPARα and PPARγ might
have some antiviral activity, we infected and cultured confluent
A549 cell monolayer in the presence of specific PPAR agonists.
The following PPARγ-specific ligands were used in our study:
the naturally occurring compound 15d-PGJ2, a metabolite of
prostaglandin D2, the synthetic antidiabetic thiazolidinedione
derivatives ciglitazone and troglitazone, and a N-protected
leucine analog designated as Fmoc-Leu (Rocchi et al., 2001).
Two molecules of Fmoc-Leu interact with one PPARγmolecule
in a highly specific manner. In addition, the PPARα-specific
agonist bezafibrate was included in this study to determine
whether activation of PPARα might also interfere with RSV
infection in airway epithelial cells.
The cells were preincubated with the PPAR agonists for
30 min, infected with RSVand then cultured for 72 h still in the
presence of the agonists. Thereafter, the cytopathic effect of
RSV was assessed by light microscopy (Fig. 2). As can be seen
from Fig. 2b, when compared with the medium control (Fig.
2a), the previously confluent cell monolayer was totally
destroyed by RSV infection. The infected monolayer showed
Fig. 1. PPARα, PPARβ, PPARγ expression in human A549 cells. Data are shown as relative fluorescence intensity (on a logarithmic scale, x axis) and number of cells
(y axis). The relevant isotype control is shown by the dotted line. The overlaid distribution histograms show a constitutive intracellular expression of all three PPAR
isoforms (A–C, thick lines). The antibody/protein complex formation was blocked by prior incubation of the PPARα and PPARγ polyclonal Abs with specific PPARα
and PPARγ blocking peptides (A and B, thin lines). Representative histograms are shown (n = 2).
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monolayers preincubated with ciglitazone, troglitazone, and
Fmoc-Leu, respectively, were totally protected from RSV-
induced cell damage (Figs. 2c–e). The natural PPARγ ligand
15d-PGJ2 showed a slight increase of adherent A549 cells when
compared to the RSV-infected monolayer cultured in mediumFig. 2. Reduced cytopathic effects in RSV-infected A549 cells cultured in the presence
ciglitazone (20 μM) (c), troglitazone (20 μM) (d), Fmoc-Leu (100 μM) (e), 15d-PGJ2
(h) for 30 min. Thereafter, cells were infected with RSV (b–h) and cultured for 72
cytopathic changes in A549 cells 72 h post-infection. Images were taken at a magnalone (Figs. 2f and b). In contrast, the PPARα agonist
bezafibrate and the vector control DMSO had no protective
impact on the RSV-induced cell damage (Figs. 2g and h).
Since HEp-2 cells are well known for their extensive
syncytia formation following RSV infection, we also analyzed
the cytopathic changes in RSV-infected HEp-2 monolayersof PPAR agonists. Confluent monolayers were preincubated with medium (a, b),
(20 μM) (f), bezafibrate (100 μM) (g), and the vector control DMSO (0.2% (v/v))
h still in the presence of the agonists. Photomicrographs are shown illustrating
ification of ×100.
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of syncytia proceeded faster and more efficiently in HEp-2
monolayer than in A549 cells, we evaluated the cell monolayers
by light microscopy already 48 h post-RSV infection. Similar to
A549 cells, pretreatment of the monolayers with ciglitazone,
troglitazone, and Fmoc-Leu (Figs. 3c–e) totally abolished the
RSV-induced syncytium formation (Fig. 3b). Furthermore,
when analyzed 48 h post-infection, the natural PPARγ ligand
15d-PGJ2 protected the HEp-2 monolayer from syncytium
formation (Fig. 3f). Again, the PPARα agonist bezafibrate and
the vector control DMSO did not influence the RSV-induced
cell fusion (Figs. 3g and h).
Similar results were obtained in A549 and HEp-2 cell
monolayers, when PPARγ ligands were added post-RSV
infection (data not shown). Taken together, all PPARγ ligands
under study fully protected the RSV-infected airway epithelial
cell monolayer from RSV-induced cell damage at least up to
48 h post-infection.
Inhibitory effect of PPARγ agonists on viral protein and mRNA
expression
To analyze whether the PPARγ ligands might have a general
inhibitory effect on the cellular protein synthesis, we deter-
mined the Toll-like receptor 2 (TLR2) expression pattern and
the release of dehydrogenases from RSV-infected cells in the
presence or absence of the agonists. As shown in Fig. 4A, the
infection with RSV led to a significant upregulation of TLR2 on
A549 cells. However, neither of the PPARγ ligands under study
modulated the RSV-induced TLR2 expression pattern. More-
over, the enzyme activity of secreted dehydrogenases deter-
mined in the harvested cell supernatants of RSV-infected A549
cells was independent of the presence of PPARγ ligands (Fig.
4B). In summary, these data suggest that the PPARγ agonists
neither inhibit the cellular protein synthesis nor have anyFig. 3. Reduced cytopathic effects in RSV-infected HEp-2 cells cultured in the prese
(a, b), ciglitazone (20 μM) (c), troglitazone (20 μM) (d), Fmoc-Leu (100 μM) (e), 1
(0.2% (v/v)) (h) for 30 min. Thereafter, cells were infected with RSV (b–h) and cultu
illustrating cytopathological changes in HEp-2 cells 48 h post-infection. Images wegeneral inhibitory effect on cell viability and/or cell metabolism
which might account for the reduced viral cytopathic effect.
The viral attachment (G) protein and fusion (F) protein,
glycoproteins incorporated in the viral envelope, are responsible
for the initial attachment and fusion of the viral envelope with
the target cell membrane. Moreover, the cytopathic effect in
tissue culture is mediated by the epithelial cell surface
expression of the viral F protein. We, therefore, analyzed
whether the observed protective effect of PPARγ ligands on
RSV-infected human lung epithelial cells might be due to a
reduced expression of these viral envelope proteins. The cells
were pretreated with PPARγ agonists, infected with RSV, and
then cultured for 36 h. As shown in Fig. 5, the expression of
both viral G and F protein was markedly reduced when cells
were cultured in the presence of ciglitazone, 15d-PGJ2, and
Fmoc-Leu, respectively. Similar to ciglitazone, troglitazone
(20 μM) markedly reduced the expression of both proteins (data
not shown). Again, the PPARα agonist bezafibrate (100 μM)
did not modulate the expression level of viral proteins on RSV-
infected cells (data not shown). To exclude that the PPARγ
agonists primarily interfere with the viral adhesion and fusion
process or may simply kill the virus, we analyzed the F protein
expression on RSV-infected A549 cells that were either
preincubated with the agonists or exposed to the agonists
subsequent to the RSV infection. Our data show that the cell
surface F protein expression was even downregulated by
PPARγ agonists which were added to the infected cells 8 h post-
infection (Fig. 6).
Next, we asked whether the diminished viral protein
expression might be associated with a reduced viral mRNA
level. For that purpose, we analyzed the cellular amount of N
protein-specific mRNA by real-time RT-PCR. Our data show
that A549 cells expressed a high amount of N protein-encoding
mRNA 36 h post-infection (Fig. 7). However, when cells were
cultured in the presence of PPARγ agonists, the cellular amountnce of PPAR agonists. Confluent monolayers were preincubated with medium
5d-PGJ2 (20 μM) (f), bezafibrate (100 μM) (g), and the vector control DMSO
red for further 48 h in the presence of the agonists. Photomicrographs are shown
re taken at a magnification of ×100.
Fig. 4. PPARγ agonists do not affect cell protein synthesis and viability. (A) The RSV-induced expression of Toll-like receptor 2 (TLR2) is not downregulated by
PPARγ agonists. Cells were pretreated either with ciglitazone (20 μM), troglitazone (20 μM), 15d-PGJ2 (20 μM), Fmoc-Leu (100 μM), bezafibrate (100 μM), the
vehicle DMSO (0.2% (v/v)), or medium, respectively for 30 min, then infected with RSV, washed, and incubated with freshly supplied agonists for 48 h. Results are
means ± SEM (n = 3). (B) PPARγ agonists did not reduce cell viability. Cells were incubated with the abovementioned agonists for 48 h. Cell viability/proliferation
after treatment with PPAR agonists was assessed by WST-1 assay. Data are shown as means ± SD of a representative experiment (n = 3) performed in quadruplicate.
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All PPARγ agonists under study reduced dose dependently the
cellular N protein mRNA level (Figs. 7A and B). Also, a
reduced G protein mRNA level was demonstrated by RT-PCR
(data not shown).Fig. 5. Reduced expression of RSV G and F protein on human A549 cells cultured wi
(left column) and F protein (right column) expression. Cells were pretreated with the a
for another 36 h. Expression of viral G and F protein on RSV-infected A549 cells cu
15d-PGJ2 (20 μM) (c, d), and Fmoc-Leu (100 μM) (e, f) (thick line), respectively. Ba
lines. The results are representative of multiple independent experiments (n = 3).PPARγ agonists diminish the replication of RSV in A549 and
NHBE cells
To investigate whether the PPARγ agonist-mediated inhibi-
tion of viral protein and gene expression results in a diminishedth PPARγ ligands. Flow cytometric analysis of cell surface bound viral G protein
gonists for 30 min, RSV-infected, and cultured still in the presence of the agonists
ltured in medium alone (thin line) or pretreated with ciglitazone (20 μM) (a, b),
ckground fluorescence signals of stained noninfected cells are shown by dotted
Fig. 6. F protein expression is diminished by PPARγ agonists added pre- and
post-RSV infection. Flow cytometric analysis of cell surface bound viral F
protein expression 48 h post-infection. A549 cells were incubated with the
PPARγ agonists troglitazone (50 μM), 15d-PGJ2 (20 μM), Fmoc-Leu (200 μM),
and the vehicle control DMSO (0.2% (v/v)), respectively. The agonists were
either added 30 min prior to RSV infection, directly thereafter (0 min post-
infection), or 4 h and 8 h post-infection. A representative experiment is shown
(n = 2).
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amount of infectious particles in the cell supernatants harvested
48 h post-infection. The cells were pretreated with differentFig. 7. PPARγ agonists downregulated the cellular amount of N protein-
encoding mRNA in RSV-infected A549 cells. (A) Cells were pretreated for 30
min with 15d-PGJ2 (10–20 μM), ciglitazone (20–40 μM), troglitazone (20–
40 μM), or with (B) Fmoc-Leu (200–400 μM) and the vehicle control DMSO
(0.1, 0.2, 0.3% (v/v)), respectively, for 30 min. Pretreated cells were infected
with RSV and cultured in the presence of the agonists for another 36 h. The
cellular amount of N protein mRNAwas quantitatively determined by real-time
RT-PCR. Results are means ± SD of samples analyzed in triplicate; in case error
bars are not visible, they are smaller than symbols shown; The results are
representatives of multiple independent experiments (n = 3).concentrations of the PPARγ agonists as well as the PPARα
agonist bezafibrate. Our data show that all used PPARγ agonists
significantly reduced the amount of infectious RSV particles in
the cell supernatants in a dose-dependent manner (Figs. 8A and
B). Especially ciglitazone and Fmoc-Leu showed the most
prominent inhibitory effect on viral replication, i.e., the virus
titer decreased by nearly 1000-fold. Furthermore, cells
immediately exposed to PPARγ agonists post-RSV infection
showed a comparable diminished release of infectious progeny
virus (data not shown). In contrast, neither the PPARα agonist
bezafibrate nor the vector control DMSO (0.05–0.3% (v/v)) did
affect the viral replication rate (Fig. 8B).
The A549 line originated from type II alveolar adenocarci-
noma cells. Although this cell line is a well-accepted in vitro
model for analyzing RSV infection in human lung epithelial
cells, we next verified whether the PPARγ agonists ciglitazone,
Fmoc-Leu, and 15d-PGJ2 might also interfere with RSV
replication in primary human bronchial epithelial cells. Similar
to a more clinical setting, we first infected NHBE cells and
cultured them thereafter for 48 h in the presence of the PPARγ
agonists. Our data show that ciglitazone, troglitazone, and the
endogenous ligand 15d-PGJ2 inhibited the replication of RSV inFig. 8. PPARγ agonists diminished the release of infectious progeny virus from
A549 cells. (A) Cells were pretreated with ciglitazone (5–50 μM), troglitazone
(5–50 μM), 15d-PGJ2 (5–20 μM) for 30 min. (B) Cells were pretreated with
Fmoc-Leu (50–300 μM), bezafibrate (50–300 μM), and the vehicle DMSO
(0.05, 0.1, 0.2, 0.3% (v/v)) for 30 min. Thereafter, cells were infected with RSV
(MOI = 3) and cultured for 48 h. Supernatants were harvested and immediately
analyzed by plaque assay on HEp-2 cells. Results are means ± SEM (n = 8); in
case error bars are not visible, they are smaller than symbols shown; *P < 0.01,
significant vs. nonpretreated RSV-infected cells.
Fig. 9. PPARγ agonists reduced the release of progeny virus and the cellular amount of RSV N protein mRNA in NHBE cells. The cells were infected with RSV
(MOI = 3) for 2 h, washed, and cultured for 48 h in the presence of the PPAR ligands ciglitazone (20 μM), troglitazone (20 μM), 15d-PGJ2 (10 μM), Fmoc-Leu
(100 μM), bezafibrate (100 μM), and the vehicle control DMSO (0.2% (v/v)), respectively. (A) Supernatants were harvested and immediately analyzed by plaque assay
on HEp-2 cells. Results are means ± SEM (n = 4); *P < 0.01, significant vs. nonpretreated RSV-infected cells. (B) Cells were harvested, and the cellular amount of
mRNA encoding for viral N protein was quantitatively determined by real-time RT-PCR. Results are means from two independent experiments.
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reduced the release of progeny virus most efficiently by nearly
1000-fold (Fig. 9A). Moreover, similar to A549 cells, the
reduced production of infectious virus particles was paralleled
by a downregulated N protein mRNA level, suggesting that
PPARγ agonists might also interfere with RSV gene expression
in NHBE cells (Fig. 9B). Similar to A549 cells, the PPARα
agonist bezafibrate and DMSO had no effect on the release of
infectious progeny virus and the cellular mRNA level encoding
for RSV N protein (Figs. 9A and B).
Discussion
In the present study, we supply evidence that the four PPARγ
agonists ciglitazone, troglitazone, 15d-PGJ2, and Fmoc-Leu,
respectively, suppress the replication of RSV in an in vitro RSV
infection model. Human lung epithelial cells of the cell line
A549 as well as primary bronchial epithelial cells showed a
significantly reduced release of infectious progeny virus. In
contrast, activation of PPARα by means of the specific agonist
bezafibrate had no impact on RSV replication.
We determined a constitutive expression of PPARα, β, and γ
in human lung A549 cells by FACS analysis. With regard to the
expression of PPARγ, our data are in accordance with data
previously published (Michael et al., 1997; Wang et al., 2001;
Pawliczak et al., 2002). However, Wang and Pawliczak argued
against a prominent expression of PPARα in human NIH-A549,
A549, and NHBE cells. In contrast, rabbit corneal epithelium
expresses PPARα and β but not γ mRNA (Bonazzi et al.,
2000). Whether our contrasting PPARα expression pattern is
due to the different antibodies used, the different sensitivities of
the detection systems, i.e., FACS analysis vs. immunoblot
technique, or the analyzed cell type or cell charge remains to be
determined.
To analyze the inhibitory effect of PPARγ agonists on RSV
production in more detail, we determined the viral protein and
mRNA expression pattern. The reduced release of infectious
progeny virus was paralleled by a downregulation of the viral F
and G protein expressed on the cell surface of the infected A549
epithelial cells. These data suggest that the observed reduced
release of progeny virus might be a direct consequence of animpaired viral protein synthesis and is obviously not due to an
altered budding process from the infected cell. It is known that
the F protein by interacting with the small GTPase RhoA is
solely responsible for the cytopathic effect primarily observed
in cell culture (Pastey et al., 1999). Therefore, the fact that all
four PPARγ agonists significantly reduced the expression of the
viral F protein is fully sufficient to account for the increased
viability and reduced cytopathic effect observed in A549, HEp-
2, and NHBE cell monolayers. When assayed 48 h post-
infection the natural ligand 15d-PGJ2 inhibited the release of
infectious progeny virus and fully protected RSV-infected HEp-
2 cell monolayer from cell damage. However, when RSV-
infected A549 cell monolayers were assayed 72 h post-
infection, the natural ligand 15d-PGJ2 protected the monolayers
to a lesser degree than the synthetic PPARγ agonists
ciglitazone, troglitazone, and Fmoc-Leu, respectively, which
cannot be explained at the present moment. The reason for that
is not known. However, little is known about the biological
activity and turnover of 15d-PGJ2 in vivo as well as in vitro lung
epithelial cell cultures up to an incubation time of 72 h. It is
assumed that 15d-PGJ2 secreted into the microenvironment of
the inflamed tissue is effectively metabolized by macrophages
and other resident cells. In line with this assumption is the
observation made by Bell-Parikh et al. (2003) that the
concentrations of 15d-PGJ2, measured in the joint fluids of
patients suffering from rheumatoid arthritis, are too low to
activate PPARγ. We, therefore, hypothesize that the loss of
protection observed in RSV-infected lung epithelial cell
monolayers cultured up to 72 h post-infection might be due to
a more effective metabolism/inactivation of 15d-PGJ2 com-
pared to the other PPARγ agonists under study. Detailed time
kinetic studies have to address this point in future.
We observed a significant inhibition of progeny virus release
when PPARγ agonists were used either as a prophylactic drug in
A549 cells or as therapeutic drug in A549 and NHBE cells, i.e.,
pre- and post-infection. By analyzing the viral protein expres-
sion, we determined that the PPARγ agonists still supply an
antiviral effectwhen added 8 h post-infection. Thus, the analyzed
PPARγ agonists did not primarily interfere with the viral
adhesion and fusion process. Our data concerning the reduced N
proteinmRNA expression level suggest that the lifecycle of RSV
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detailed molecular mechanisms leading to the reduced viral gene
expression pattern are still not known. However, a general
inhibitory effect on the cellular protein and/or mRNA synthesis
rate can be ruled out since the PPARγ agonists did not interfere
either with cell viability or the RSV-induced upregulation of
TLR2.
Recently, the direct activation of PPARγ in A549 cells either
by 15d-PGJ2 (1–5 μM) or ciglitazone (5–25 μM) was
demonstrated by Wang et al. (2001). Therefore, we did not
reproduce these data. However, in agreement with other
published results analyzing the anti-inflammatory and antiviral
capacities of thiazolidinediones and 15d-PGJ2, we also used
with respect to their PPARγ-binding constants relatively high
concentrations of the agonists to influence RSV production
(Hayes et al., 2002; Kwak et al., 2002). One may argue that
natural and synthetic PPARγ agonists also exert part of their
anti-inflammatory activity by interfering with a variety of other
signal transduction pathways in a PPARγ-independent manner.
Especially, the modulation of the Janus/STAT and MAP kinase
signaling pathways has been reported (Takeda et al., 2001; Chen
et al., 2003). In this regard, it was recently published that
activation of ERK1 and 2 is a prerequisite for a successful
replication of RSV (Kong et al., 2004). Therefore, PPARγ
agonist-mediated modulation of MAP kinase activity might
contribute to the observed antiviral effect. In addition, whether
the RSV-induced inhibition of the antiviral cellular α/β-
interferon response, mediated by the NS1 and NS2 proteins,
might be counter-regulated by the PPARγ agonists should also
be addressed in future experiments (Bossert et al., 2003; Spann
et al., 2004; Lo et al., 2005).
The fact that PPARγ agonists are able to modulate the
activity of other transcription factors is well demonstrated
(Straus et al., 2000; Përez-Sala et al., 2003). Recently, we
observed that all PPARγ agonists under study profoundly
reduced the binding activity of NF-κB (p65/p50) in RSV-
infected cells (Arnold and König, in press). Quite recently,
Bailey and Ghosh (2005) published data that PPARγ agonists,
which induce sumoylation of PPARγ, prevent the degradation
of the NF-κB-bound coreceptor complex thereby excluding its
exchange by a coactivator complex. This leads to a transrepres-
sion of the NF-κB-dependent promoters. However, no data are
available which support the notion that a reduced NF-κB
activity interferes with the replication of RSV (Fiedler et al.,
1996). Nevertheless, the reduced NF-κB binding activity
correlated with a diminished release of proinflammatory
cytokines (IL-1α, IL-6, TNF-α) and chemokines (CXCL8 and
CCL5) from RSV-infected lung epithelial cells (Arnold and
König, in press). Furthermore, a reduced cell surface expression
of ICAM-1 and MHC-I was observed (our own unpublished
data). Currently, there exist no satisfactory anti-inflammatory
treatment for RSV infection. Corticosteroids have been shown
to have little to no effect in the overall outcome of RSV
infection (Bonville et al., 2001). In contrast, several studies have
clearly demonstrated that PPARγ agonists have additional anti-
inflammatory effects compared to corticosteroids. In this regard,
Patel et al. (2003) reported that PPARγ agonists, but notdexamethasone, inhibited the release of G-CSF from human
airway smooth muscle cells. Furthermore, the accumulation of
huge amounts of PMN in the RSV-infected lung is a hallmark of
severe lower respiratory tract disease (Everard et al., 1994).
Quite recently, it was published that the neutrophil infiltration of
the lung was significantly reduced by the application of PPARγ
agonists during bleomycin-induced mouse lung injury (Genov-
ese et al., 2005). Moreover, it has been shown in a murine LPS-
induced airway inflammation model that the thiazolidinedione
compound rosiglitazone, in contrast to dexamethasone, reduced
the neutrophil number in the lung tissue when administered
after the LPS insult (Birrell et al., 2004). A direct anti-
inflammatory effect of PPARγ agonists on neutrophil and
eosinophil cell function was also reported (Woerly et al., 2003;
Imamoto et al., 2004).
In summary, proinflammatory immune effector mechanisms
as well as direct cytopathic effects contribute to the overall
outcome of RSV-induced lower respiratory tract disease. Our
data presented herein, together with our previously published
anti-inflammatory capacity of PPARγ agonists on the native
immune response of the RSV-infected lung epithelial cell,
suggest that PPARγ agonists might have a beneficial effect in
the course of an acquired RSV infection.
Materials and methods
Compounds
The PPAR agonists ciglitazone, troglitazone, bezafibrate,
Fmoc-Leu (Merck Biosciences, Schwalbach, Germany), and
15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) (Biomol, Ham-
burg, Germany) were stored in DMSO (Sigma, Deisenhofen,
Germany) at −80 °C. At the day of experiment, compounds
were freshly diluted in basal medium (DMEM or BEGM) and
added to the cells with a final DMSO concentration of 0.05–
0.3% (v/v).
Cell culture
Human A549 pulmonary type II epithelial cells (passages 4–
20) and HEp-2 cells (American Type Culture Collection
(ATCC), Rockville, MD, USA) were cultured in Dulbecco's
modified eagle medium (DMEM) (4500 mg/l D-glucose)
supplemented with 2 mM glutamine, 5% (v/v) inactivated
fetal calf serum (FCS), streptomycin (100 μg/ml), and penicillin
(100 IU/ml). Normal human bronchial epithelial cells (NHBE)
(Cambrex/Clonetics, Verviers, Belgium) were cultured in
complete BEGM medium (5 μg/ml insulin, 0.5 μg/ml
hydrocortisone, 10 μg/ml transferrin, 6.5 ng/ml triiodothyro-
nine, 0.5 μg/ml epinephrine, 0.5 ng/ml human epidermal growth
factor, 0.1 ng/ml retinoid acid, 50 μg/ml gentamicin, and 52 μg/
ml bovine pituitary extract). NHBE cells were cultured and
expanded according to the instructions of the manufacturer. To
support cell attachment and growth of NHBE cells, tissue
culture flasks and plastic plates (Greiner, Frickenhausen,
Germany) were precoated with fibronectin (10 μg/ml)
(Sigma) for 30 min at 37 °C. Cells of passages 3–7 were
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complete medium. All cell cultures and prepared virus stocks
were free of mycoplasmic contamination routinely verified by a
commercially available mycoplasma detection kit (Roche
Diagnostics, Mannheim, Germany).
Virus growth and preparation
The Long strain of RSV (ATCC) was propagated and titrated
in HEp-2 cells. The Long strain was used, as this strain is
capable of causing severe disease in human infants. For virus
propagation, confluent monolayers were infected with RSV
(MOI = 0.1) for 3 h in DMEM without FCS. The monolayers
were washed, overlayed with DMEM (0.5% FCS), and
incubated at 37 °C in 5% CO2 atmosphere until cytopathic
effect reached ∼80%. Thereafter, the supernatants were
harvested, and cellular debris was removed by centrifugation
(5000 × g, 10 min). RSV was concentrated by polyethylene
glycol precipitation (10%) and purified by means of discontin-
uous sucrose gradient centrifugation (Ueba, 1978). To stabilize
the purified virus particles, they were resolved in 20% sucrose/
NT-buffer (150 mMNaCl, 50 mM Tris–HCl, pH 7.5) and stored
at −80 °C. No contaminating cytokines, including IL-1α, TNF-
α, IL-6, IL-8, RANTES, GM-CSF, and interferonα/β, were
detected in these sucrose-purified viral preparations. Also, virus
stocks and media were free of lipopolysaccharide routinely
assayed by the Limulus hemocyanin agglutination assay
(Sigma).
RSV titration
For virus titration prepared RSV stock solutions and
harvested A549 cell supernatants were serially tenfold diluted
onto confluent HEp-2 monolayers cultured in 96-well flat-
bottomed plates. The virus titer was quantified as previously
described (Arnold et al., 2004). Briefly, infected cells were
cultured for 48 h under methyl cellulose. Then monolayers were
fixed with paraformaldehyde (2%) and stained with mouse anti-
P protein mAb (clone: 3C4, kindly supplied by Dr. H. Werchau,
Department of Medical Virology, Ruhr-University, Bochum,
Germany). Binding of the primary Ab was detected by a second
staining with HRP-conjugated rabbit anti-mouse Ab (Dako,
Hamburg, Germany). Thereafter, RSV plaques were visualized
by colorimetric staining, counted microscopically and
expressed as log10 plaque forming unit (pfu)/ml. The stock
titer of the used virus pool was 108 pfu/ml.
Cell experiments
Epithelial cells (A549 and NHBE cells) were seeded in 24-
well (1 × 105 cells/well) culture plates and cultured overnight in
DMEM and BEGM, respectively. If not stated otherwise,
confluent monolayers were washed with basal medium and
pretreated with PPAR agonists for 30 min prior to RSV
adsorption. The cells were treated with varying doses of
ciglitazone (5–50 μM), troglitazone (5–50 μM), 15d-PGJ2 (5–
20 μM), Fmoc-Leu (50–300 μM), bezafibrate (50–300 μM),and solvent (DMSO; 0.05–0.3% (v/v)), respectively, in a
volume of 1 ml. Thereafter, the medium was reduced to a
volume of 200 μl, and cells were infected with RSV for 2 h still
in the presence of the used PPAR agonists. The virus stock was
diluted in culture medium to a defined multiplicity of infection
(MOI) of 3. An equivalent amount of 20% sucrose/NT-buffer
added to noninfected cells served as mock control. Then, cells
were washed and incubated with fresh medium (DMEM (2%
FCS) or supplemented BEGM in case of NHBE cells) in the
presence of freshly supplied agonists for another 36 h–72 h. In
addition, RSV-infected cells were incubated with PPAR agonists
post-RSV infection. Thereafter, cells were detached and
harvested as previously described (Arnold and König, 2005).
As was determined by a modified 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay, designated as
WST-1 assay (Roche), the added agonists induced no significant
cell death (>3%) at the concentrations used (data not shown).
Quantification of cell proliferation and cell viability
Confluent A549 cell monolayers (5 × 104 cells/well) placed
in 96-well flat-bottomed plates were incubated with the agonists
for 48 h. For control, cells were incubated with the vehicle
DMSO alone. Cell viability and cell proliferation was
determined by analyzing the cleavage of the tetrazolium salt
WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazo-
lio]-1,3-benzene disulfonate) to formazan by mitochondrial
dehydrogenases (Roche). A reduction in the number of viable
cells results in a decrease in the overall activity of mitochondrial
dehydrogenases in the cell supernatant. This reduced enzyme
activity leads to a reduced amount of formazan dye formed,
which directly correlates to the number of metabolically active
cells in the culture. Briefly, 10 μl of a ready to use solution was
added to 100 μl (1:10 final dilution) for the last 1 h of
incubation. The plate was directly read at 450 nm against a
reference wavelength of 620 nm on a SpectraFluorPlus Reader
(Tecan, Crailsheim, Germany).
FACS staining
The constitutive intracellular expression of PPARs in
noninfected A549 cells was analyzed by flow cytometry. By
using the Fix and Perm kit for intracellular staining (BD
Biosciences (BD), Heidelberg, Germany), the cells were fixed
and permeabilized according to the manufacturer's instructions.
Thereafter, the cells were washed two times in permeabilization
washing buffer and analyzed with the primary unlabeled
polyclonal rabbit anti-PPARα-Ab, rabbit anti-PPARγ-Ab (Cay-
man Chemicals, Ann Arbor, MI, USA), rabbit anti-PPARβ Ab
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), and
unspecific rabbit IgG (Sigma), respectively, for 1 h at 4 °C.
Then, primary bound Abs were detected by secondary staining
with PE-labeled AffiniPure F(ab′)2 fragment of goat anti-rabbit
IgG (H + L) (Dianova, Hamburg, Germany) for 1 h at 4 °C. To
determine binding specificity of the used primary anti-PPARα
and anti-PPARγ Abs, we blocked antibody/protein complex
formation by using PPARα- and PPARγ-specific blocking
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manufacturer, prior to cell staining, the blocking peptides
(0.5 mg/ml) were mixed with Abs in a 1:1 (v/v) ratio and
incubated for 60 min. To determine RSV protein synthesis in
RSV-infected A549 cells, the cells were analyzed for cell surface
expression of viral G and F protein (Arnold and König, 2005).
Binding of monoclonal mouse anti-G protein and anti-F protein
Ab (Biotrend, Köln, Germany) was visualized by a second
staining with Cy3-labeled AffiniPure goat anti-mouse IgG
(H + L) (Dianova). The expression of TLR2 was determined
with a PE-labeled monoclonal mouse anti-TLR2 Ab
(eBioscience, San Diego, USA). The corresponding unlabeled
and labeled mouse IgG subtypes served as isotype controls
(BD). After cell washing, the cell bound fluorescence signal was
determined by FACSCalibur (BD), and data were analyzed by
means of CellQuest software (BD). The mean fluorescence
intensity (MFI) of 10,000 cells was determined and corrected by
subtraction of background fluorescence of the isotype control.
RNA extraction and real-time RT-PCR
The total cellular RNA from noninfected and RSV-infected
epithelial cells (5 × 105) was extracted using the QiAmp 96 viral
RNA Biorobot kit on the Biorobot 3000 System from Qiagen
(Düsseldorf, Germany). Reverse transcription (RT)-PCR was
performed with M-MLV RT-buffer components (Invitrogen,
Karlsruhe, Germany). Prepared total RNA (2 μg) was added to
50 μl PCR reaction mix consisting of 50 mM Tris–HCl buffer
(pH 8.3), 3 mM MgCl2, 75 mM KCl, 10 mM DTT, 500 μM
dNTPs, 2 ng/μl oligo d(T)(12–18), 1 U/μl RNAase inhibitor
(Applied Biosystems, Foster City, CA, USA), and 4 U/μl M-
MLV. The synthesis of cDNA was performed at 37 °C for
60 min. The cDNA was stored at −20 °C.
The amount of RSV N protein mRNA was quantified by
Taqman real-time RT-PCR as previously reported (Dewhurst-
Maridor et al., 2004). Briefly, using the Gene Amp 5700
Sequence Detector (Applied Biosystems) the RNA (100 ng) was
reverse transcribed to 2.5 μl cDNA and amplified in a volume of
25 μl by means of TaqMan Universal PCRMaster Mix (Applied
Biosystems) containing specific primers for RSV N protein and
a fluorescently labeled probe synthesized by Metabion (Pla-
negg-Martinsried, Germany): forward, 5′-CTCAATTTCCT-
CACTTCTCCAGTGT-3′; reverse, 5′-CTTGATTCCTC-
GGTGTACCTCTGT-3′; probe, 5′-6-carboxy-fluorescein
(FAM)-TCCCATTATGCCTAGGCCAGCAGCA-6-carboxy-
tetramethyl-rhodamine-(TAMRA)-3′. The cDNAwas denatured
at 95 °C for 10 min and amplified by 40 cycles (95 °C, 15 s and
60 °C, 1 min). Concentrations of primers and probes were
optimized to obtain a reaction yield at the lowest threshold cycle
and a high cycle to cycle increase of the resulting fluorescent
signal (ΔRn). The primers were used at a concentration of
300 nM together with the probe diluted to 200 nM. The primer/
probe set for the housekeeping gene human GAPDH was
supplied as a predeveloped kit by Qiagen. The reaction
components were mixed and the amplification profile settled
according to the instructions of the manufacturer. Negative
controls were carried out with water instead of cDNA. ThecDNA prepared from RSV-infected cells and diluted up to 105
served as a positive control validating that the efficiencies of the
RSV N protein and GAPDH PCR were approximately equal.
Expression of GAPDH gene was not significantly altered during
the time of incubation with RSV, drugs and vehicle. Therefore,
the relative mRNA expression of each gene was normalized to
the level of GAPDH in the same RNA preparation, i.e., the
comparative CT method was used to analyze the relative
quantities of RSV N protein mRNA in cell samples. The relative
RNA amount was calculated by using the following equation:
2−ΔΔCT were ΔΔCT = ΔCT,q − CT,cb. CT is defined as the CT
value for RSV N protein minus the CT value for GAPDH for a
given sample, q is the unknown sample, and cb is the calibrator
(noninfected sample).
Statistics
If not stated otherwise, data were expressed as the
mean ± SEM. For statistical significance, analysis of data was
performed using Student's t test (two-sided). A value of
P < 0.05 was considered significant.
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